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Abstract
Introduction Rheumatoid arthritis (RA) is more common in
females than males and sex steroid hormones may in part explain
this difference. We conducted a case–control study nested
within two prospective studies to determine the associations
between plasma steroid hormones measured prior to RA onset
and polymorphisms in the androgen receptor (AR), estrogen
receptor 2 (ESR2), aromatase (CYP19) and progesterone
receptor (PGR) genes and RA risk.
Methods We genotyped AR, ESR2, CYP19, PGR SNPs and
the AR CAG repeat in RA case–control studies nested within
the Nurses' Health Study (NHS), NHS II (449 RA cases, 449
controls) and the Women's Health Study (72 cases, and 202
controls). All controls were matched on cohort, age, Caucasian
race, menopausal status, and postmenopausal hormone use.
We measured plasma dehydroepiandrosterone sulfate
(DHEAS), testosterone, and sex hormone binding globulin in
132 pre-RA samples and 396 matched controls in the NHS
cohorts. We used conditional logistic regression models
adjusted for potential confounders to assess RA risk.
Results Mean age of RA diagnosis was 55 years in both
cohorts; 58% of cases were rheumatoid factor positive at
diagnosis. There was no significant association between plasma
DHEAS, total testosterone, or calculated free testosterone and
risk of future RA. There was no association between individual
variants or haplotypes in any of the genes and RA or
seropositive RA, nor any association for the AR CAG repeat.
Conclusions Steroid hormone levels measured at a single time
point prior to RA onset were not associated with RA risk in this
study. Our findings do not suggest that androgens or the AR,
ESR2, PGR, and CYP19  genes are important to RA risk in
women.
ACR: American College of Rheumatology; AR: androgen receptor gene; CYP19: aromatase gene; DHEAS: dehydroepiandrosterone sulfate; ESR2: 
estrogen receptor 2 gene; htSNP: haplotype-tagged single nucleotide polymorphism; IL: interleukin; NHS: Nurses' Health Study; PGR: progesterone 
receptor gene; RA: rheumatoid arthritis; SHBG: sex hormone binding globulin; SNP: single nucleotide polymorphism; TNF: tumor necrosis factor; 
WHS: Women's Health Study.Arthritis Research & Therapy    Vol 11 No 3    Karlson et al.
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Introduction
Women are two to four times more likely than men to develop
rheumatoid arthritis (RA) [1,2], and sex hormones including
androgens, estrogen, and progesterone may be related to this
disparity [3,4]. In women and men the age-related increased
incidence of RA parallels the decline in androgen production
[5]. Cross-sectional studies of serum androgen levels demon-
strate low serum testosterone levels and dehydroepiandros-
terone sulfate (DHEAS) in RA patients compared with healthy
individuals [6-10]. Serum testosterone levels are inversely cor-
related with RA disease activity [11], and DHEAS levels are
inversely correlated with both disease duration and clinical
severity of RA [12]. Androgen receptor expression is signifi-
cantly higher in RA synovial tissue compared with that in non-
inflamed synovial tissue [13]. In synovial fluid from active RA
patients compared with control individuals, there is evidence
of higher free estrogen, lower free androgen levels, and locally
elevated aromatase activity [14]. Small randomized controlled
trials of testosterone treatment demonstrate significantly
improved RA symptoms in women with RA [15] and in men
with RA [16]. Whether low androgen levels precede the onset
of RA or are simply the result of the disease or its treatment is
not clear. One small prospective study demonstrated low
DHEAS among premenopausal pre-RA women compared
with control individuals [17], while another study demon-
strated no differences in total testosterone or DHEAS levels in
male and female pre-RA cases compared with sex-matched
control individuals [18].
Androgens have immunosuppressive effects on both the
humoral and cellular immune response [19-24]. The female
sex predominance in RA may be related to low androgen levels
prior to disease onset since adrenal and gonadal androgen
deficiency can trigger inflammatory cytokines such as TNFα
and IL-6, key cytokines responsible for the inflammatory
response in RA [25]. Alternatively, androgens may influence
RA risk indirectly through conversion to estradiol by aromatase
or directly by binding to the androgen receptor and affecting
cell proliferation. We hypothesized that low total and free tes-
tosterone levels and low DHEAS levels measured before the
onset of disease would be associated with an increased risk
of RA in women.
Excess estrogen and progesterone may have a protective role
in RA etiology. Women are at decreased risk of developing RA
during pregnancy, when estrogen and progesterone levels are
high. The 12-month postpartum period, particularly the first 3
months, represents a period of increased risk, however, when
estrogen and progesterone levels fall dramatically [26]. Pro-
gesterone, as well as estrogen and androgens, may therefore
play a role in RA pathogenesis.
Based on the hypothesis that a low androgen–estrogen bal-
ance is associated with RA in women [3,4], we investigated a
number of hormone receptor genes involved in androgen–
estrogen pathways for association with RA. The estrogen
receptor, the androgen receptor and the progesterone recep-
tor are members of the nuclear receptor superfamily, which
depend on ligand binding for activation.
The androgen receptor gene (AR) located on chromosome X
encodes the androgen receptor, and upon androgen binding
the activated androgen–androgen receptor complex activates
the expression of other genes via ligand binding, homodimeri-
zation, nuclear translocation, DNA binding, and formation of
complexes with co-activators and co-repressors [27]. Exon 1
contains a polymorphic CAG repeat sequence that correlates
inversely with AR  transactivational activity [28,29]. Shorter
CAG repeat polymorphisms (more active receptor) in AR are
associated with higher serum androgen levels among premen-
opausal women [30].
When androgens are converted to their corresponding estro-
gens, the effects are mediated by estrogen receptors 1 and 2.
The estrogen receptor 2 gene (ESR2) is located on chromo-
some 14q22-24. Estrogen receptors are highly expressed on
synovial cells [13] and are found on T lymphocytes [31].
The progesterone gene (PGR) is a single-copy gene located
on chromosome 11q22-23 [32] and has two identified iso-
forms, PGR-A and PGR-B [33,34]. Progesterone downregu-
lates the production of the inflammatory chemokine IL-8 at the
transcriptional level [35]. The polymorphism (+331G/A), iden-
tified by our group [36], creates a novel transcription start site
that increases transcriptional activity and alters the PGR iso-
form ratio. The anti-inflammatory role of the progesterone
receptor is mediated by PGR-A; however, in the presence of
the variant (isoform A) there is overproduction of the PGR-B
isoform [36].
The aromatase gene (CYP19) encodes aromatase, which cat-
alyzes the aromatization of the androgens androstenedione
and testosterone to estrone and estradiol, respectively. Aro-
matase has been found in synoviocytes [37]. Data from Cutolo
and colleagues suggest an accelerated peripheral metabolic
conversion of upstream androgen precursors to 17β-estradiol
occurs in RA [3], perhaps via inflammatory cytokines that
markedly stimulate aromatase activity in peripheral tissues
[38,39]. Moreover, genetic variants in CYP19  have been
shown to influence endogenous estrogen levels [40].
The overall goal of the present study is to define the contribu-
tion of sex-steroid hormone levels measured in plasma sam-
ples collected prior to the onset of RA, and the role of genetic
variants in hormones in the steroid pathway in RA etiology. We
aimed specifically to assess the association between plasma
hormone levels for total testosterone, free testosterone, and
DHEAS, as well as genetic polymorphisms in the androgen
receptor (AR), estrogen receptor 2 (ESR2), progesterone
receptor (PGR), CYP19 and risk of RA in women. The studyAvailable online http://arthritis-research.com/content/11/3/R97
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pools data and analysis of prospective collected blood sam-
ples from several large female cohorts, the Nurses' Health
Study (NHS), the NHS II, and the Women's Health Study
(WHS).
Materials and methods
Study population
The NHS is a prospective cohort of 121,700 female nurses,
aged 30 to 55 years in 1976. From 1989 to 1990, 32,826
(27%) NHS participants aged 43 to 70 years provided blood
samples for future studies. Further, among women who did not
give blood in 1989 to 1990, 33,040 provided buccal cell sam-
ples (27% of NHS) for a total of 65,866 DNA samples (54%
of the cohort).
The NHS II is a similar prospective cohort, established in
1989, with 116,609 female nurses aged 25 to 42 years.
Between 1996 and 1999, 29,611 (25%) NHS II cohort mem-
bers, aged 32 to 52 at that time, also agreed to provide blood
samples for future studies. For the NHS cohorts, blood sam-
ples were collected in heparinized tubes and were sent by
overnight courier in chilled containers.
The WHS was a randomized, double-blind, placebo-control-
led trial designed to evaluate the benefits and risks of low-
dose aspirin and vitamin E in the primary prevention of cardio-
vascular disease and cancer among 39,876 female health pro-
fessionals, aged 45 years and older, conducted between
1992 and 2004 [41-43]. Following the end of the trial, women
who were willing to continue participated in an observational
follow-up study. From 1992 through 1995, 28,345 women in
the WHS provided blood samples in ethylenediamine
tetraacetic acid tubes. On receipt, the blood samples were
centrifuged, aliquoted into plasma, red blood cells, and buffy
coat fractions, and stored in the vapor phase of liquid nitrogen
freezers since collection.
All women in these cohorts completed an initial questionnaire
regarding diseases, lifestyle, and health practices, and have
been followed biennially in the NHS cohorts and annually in
the WHS cohort by questionnaire to update exposures and
disease diagnoses. All subjects provided informed consent.
All aspects of this study were approved by the Partners'
HealthCare Institutional Review Board.
Identification of rheumatoid arthritis
As previously described [44], we confirmed self-reports of RA
based on the presence of RA symptoms on a connective tis-
sue disease screening questionnaire [45] and based on med-
ical record review for American College of Rheumatology
(ACR) classification criteria for RA [46]. Subjects with four of
the seven ACR criteria documented in the medical record
were considered to have definite RA. For this nested case–
control study, we also included a small number of subjects (n
= 14) with agreement by two rheumatologists on the diagno-
sis of RA who had three documented ACR criteria for RA and
a diagnosis of RA by their physician.
Population for analysis
For both cases and controls, we excluded women who
reported any cancer (except nonmelanoma skin cancer) at
baseline or during follow-up, as cancer and its treatment can
affect biomarker levels. In the NHS/NHS II, each case with
confirmed incident or prevalent RA with buccal samples was
matched on year of birth, race/ethnicity, menopausal status,
and postmenopausal hormone use to a single healthy woman
in the same cohort without RA. In the WHS, we matched each
case to three controls on the same factors. For plasma hor-
mone assays and DNA from buffy coat samples, three controls
for each confirmed incident RA case in the NHS cohorts were
randomly chosen from subjects with stored blood, matching
on the same factors plus time of day and fasting status at
blood draw. For premenopausal women in NHS II, we also
matched on timing of blood sample in the menstrual cycle. To
minimize potential population stratification, we limited the anal-
yses to Caucasians for genetic analyses.
Laboratory assays
The laboratories selected for this study had high assay preci-
sion. The laboratories underwent rigorous pilot testing with
blinded aliquots from NHS specimens. The laboratory staff
were blinded to the case–control status in study samples.
Samples were labeled by number only, and matched case–
control pairs were handled together identically, shipped in the
same batch, and assayed in the same run. The order within
each case–control pair was random. Aliquots from pooled
quality-control specimens, indistinguishable from study speci-
mens, were interspersed randomly among case–control sam-
ples to monitor quality control.
Total testosterone was assayed by specific radioimmunoassay
with a solvent extraction step before celite column chromatog-
raphy [47] at Quest Laboratory, San Juan Capistrano, Califor-
nia. Performance of this assay at Quest Laboratory has been
extensively tested in prior NHS study samples with hormone
stability studies, test–retest studies, testing duplicate sam-
ples, and embedding samples with known values within stud-
ies. DHEAS was measured by radioimmunoassay (Diagnostic
Systems Laboratories, Webster, TX, USA) at Children's Hos-
pital, Rifai Laboratory (Boston, MA, USA). Sex hormone bind-
ing globulin (SHBG) was assayed using a fully automated
system (Immulite; DPC, Inc., Los Angeles, CA, USA) at the
Reproductive Endocrinology Laboratory at Massachusetts
General Hospital, using a solid-phase two-site chemilumines-
cent enzyme immunometric assay. SHBG levels were used to
calculate free testosterone levels [48].
The interassay coefficient of variations for quality-control sam-
ples were 14% for testosterone, 13% for SHBG, and 4% for
DHEAS. Hormone assays were performed in the NHS cohortsArthritis Research & Therapy    Vol 11 No 3    Karlson et al.
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but were not performed in the WHS cohort due to nonsignifi-
cant findings in the NHS.
DNA extraction
DNA was extracted from buffy coats or from buccal cell sam-
ples (collected by mouthwash swish and spit procedures) and
processed via the QIAmp™ (QIAGEN Inc., Chatsworth, CA,
USA) 96-spin blood kit protocol. All genomic DNA samples
had an aliquot put through a whole-genome amplification pro-
tocol using the GenomPhi DNA amplification kit (GE Health-
care, Piscataway, NJ, USA) to yield high-quality DNA sufficient
for SNP genotyping.
SNP genotyping
DNA was genotyped using Taqman SNP allelic discrimination
on the ABI 7900HT using published primers. We used data
from the National Cancer Institute Breast and Prostate Cancer
Cohort consortium or from the Multi-Ethnic Cohort to select
haplotype tagging SNPs for our study [49-51]. SNPs were
selected based on resequencing the coding exons of AR,
ESR2, and CYP19 in a panel of 95 women from the Multi-Eth-
nic Cohort (19 each from African Americans, Latinos, Japa-
nese, Americans, Native Hawaiians and Whites), with invasive,
non-localized breast cancer. SNPs with minor allele frequency
>5% overall or >1% in any one ethnic group were selected
from this resequencing as well as those available in the
National Center for Biotechnology Information database of sin-
gle nucleotide polymorphisms [52] from the nonsequenced
areas to be used to select haplotype tagging SNPs. The link-
age disequilibrium structure was determined by genotyping
SNPs among a reference panel of 349 women from Multi-Eth-
nic Cohort populations (including 70 Whites). Haplotype fre-
quency estimates were constructed from the genotype data
for Whites using the expectation-maximization algorithm to
select tag SNPs that maximize prediction of common haplo-
types (at R2
H ≥ 0.7, a measure of correlation between SNPs
genotyped and the haplotypes they describe).
We selected six haplotype-tag single nucleotide polymor-
phisms (htSNPs) that have been identified to capture the
genetic variation in the AR  gene in Caucasians [49]
(rs962458, rs6152, rs1204038, rs2361634, rs1337080,
and rs1337082), in three haplotype blocks, and considered
these as an extended haplotype block [53]. The htSNPs pro-
vide a minimum R2
H of 0.77 to describe the haplotype diversity
among Japanese, Whites, and Latinas from the Multi-Ethnic
Cohort selection panel [49]. Genotyping for the AR  CAG
repeat polymorphism was performed as previously described
[53]. We selected five htSNPs that have been identified to
capture the genetic variation in the ESR2 gene in Caucasians
[50] (rs3020450, rs1256031, rs1256049, G1730A, and
rs944459). The selected htSNPs have a minor allele fre-
quency of 5% or more and R2
H >0.7. Three haplotype blocks
span the ESR2  locus and are highly correlated (r  >0.95),
allowing the analysis of the htSNPs as one block. Based on a
report from the Multi-Ethnic Cohort on CYP19  haplotype
structure and breast cancer risk, we selected 20 SNPs tag-
ging four haplotype blocks, and R2
H >0.7 for association with
RA risk [40]. These htSNPs were genotyped in HapMap CEU
trios to permit an assessment of coverage in relation to the
HapMap database (phase II, October 2005) and were esti-
mated to predict 70% of all common SNPs genotyped in the
HapMap CEU population across the four linkage disequilib-
rium blocks. The variants selected for PGR were based on
functional studies performed by co-investigator IDV
[36,54,55] rather than a haplotype tagging method. Nonethe-
less these SNPs captured 90% of variation in the NHS sam-
ples, a predominantly Caucasian population [36,54,55].
Covariate information
Age was updated in each cycle. Reproductive covariates were
chosen based on our past findings of associations between
reproductive factors and the risk of developing RA in the NHS
[56]. Data on pack-years of smoking (product of years of
smoking and packs of cigarettes per day), parity, total duration
of breastfeeding (not available in the WHS), age at menarche,
menopausal status and postmenopausal hormone use were
selected from the questionnaire cycle prior to the date of RA
diagnosis (or index date in control individuals).
Statistical analyses
For analysis of characteristics of cases and controls, we cal-
culated means with standard deviation for continuous varia-
bles stratified by cohort. For categorical covariates, we
calculated frequencies and percentages. SAS version 9.1.3
software (SAS Institute, Cary, NC, USA) was used for all anal-
yses.
Analyses of hormonal factors
We calculated means with standard deviation and medians
with range for total testosterone, calculated free testosterone
and DHEAS. Threshold values for the quartiles for each hor-
mone were created using the distribution in control individuals.
We conducted conditional logistic regression models, condi-
tioned on the matching factors, and adjusted for potential con-
founders including cigarette smoking and reproductive factors
assessed prior to diagnosis of RA for total testosterone, calcu-
lated free testosterone and DHEAS, comparing quartiles of
continuous hormone levels to estimate relative risks and 95%
confidence intervals of RA in the NHS. We repeated the anal-
yses stratified by menopausal status, and by seropositive sta-
tus.
Analyses of gene–hormone associations
Analysis of covariance models were used to evaluate the asso-
ciation of the six AR htSNPs and AR CAG repeat length with
mean plasma hormone levels adjusting for potential confound-
ers, among 89 control samples with both genetic and hor-
mone information in the two NHS blood cohorts. For the total
testosterone and calculated free testosterone models, weAvailable online http://arthritis-research.com/content/11/3/R97
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adjusted for age, body mass index, menopausal status, hor-
mone use and cigarette smoking (never, former, current <15
cigarettes per day and current ≥ 15 cigarettes per day). For
DHEAS models, we adjusted for the same covariates as well
as the time of day of blood draw.
Analyses of genetic factors
We verified Hardy–Weinberg equilibrium for each of the gen-
otypes among control individuals in each of the datasets (NHS
blood, NHS cheek cells, NHS II blood, WHS blood). We
employed conditional logistic regression analyses, condi-
tioned on matching factors, and adjusted for potential con-
founders, including cigarette smoking and reproductive
factors assessed prior to diagnosis of RA. All analyses were
first conducted separately in each cohort and then on data
pooled from the three cohorts. As the P value for heterogene-
ity was not significant for the AR, ESR2, PGR, or CYP19 gen-
otypes, we also meta-analytically pooled results from the two
cohorts using a DerSimonian and Laird random-effects model
[57]. In addition, analyses were repeated stratifying by rheu-
matoid factor status of the RA cases.
We determined common haplotypes in cases and controls
using PROC HAPLOTYPE in SAS Genetics. The haplotype
dosage estimate was computed using individual genotype
data and haplotype frequency estimates from the entire data-
set. We pooled rare haplotypes (<5% frequency) into a single
category. Conditional logistic regression analyses conditioned
on matching factors, and adjusted for potential confounders,
were performed for block-specific haplotype associations with
RA risk. A likelihood ratio test was performed to test for global
haplotype associations, using the most common haplotype as
the reference category.
Cochran–Mantel-Haenszel chi-square tests were conducted
to evaluate case–control differences in the frequency of the
AR CAG alleles using multiple cutoff points. In most analyses,
we used the cutoff point (CAG)n ≥ 22 repeats, which has been
most frequently used in the literature. We used conditional
logistic regression adjusted for potential confounders to
assess the increase in log odds of RA per unit increase in
CAG repeat, and also examined various cutoff points for
repeat length in similar models.
Analyses of gene–smoking interactions
We assessed gene–smoking interactions using a multiplica-
tive interaction variable (for example, genotype × smoking) in
the conditional logistic regression models. The significance of
the interaction was determined using the Wald chi-square test
of the interaction variable. In the combined NHS–NHS II
nested case–control study dataset, we assessed for interac-
tions between the presence of each polymorphism and ciga-
rette smoking dichotomized as ≤ 10 or >10 pack-years of
smoking to account for heavy smoking, as this is the threshold
we previously identified to be associated with increased risk of
RA [44]. In the WHS cohort we assessed for interaction
between polymorphisms and ever/never smoking, as pack-
year information was not available.
Results
Genetic analyses were limited to Caucasian matched pairs to
minimize the potential for population stratification. In the NHS
cohorts, we confirmed 449 Caucasian RA cases with available
DNA and 132 cases with available plasma samples collected
prior to first RA symptoms (preclinical RA). In chart reviews,
433 cases had at least four ACR criteria, 14 cases had at least
three ACR criteria, and all cases had two rheumatologist
reviewers' consensus on RA diagnosis. In the WHS cohort,
we confirmed 72 Caucasian RA cases with stored samples.
Fifty-eight percent of RA cases in both the NHS and WHS
cohorts were rheumatoid factor positive by chart review. In the
132 pre-RA cases with plasma, the mean time between blood
draw and RA symptoms was 6.8 years (range = 0 to 14.2
years). The distribution of potential confounders was similar
among cases and controls (Table 1). Among RA cases, 179
(67%) were postmenopausal in the NHS cohort and 39 (54%)
were postmenopausal in the WHS cohort at blood draw.
Plasma androgens in cases compared with controls in 
the NHS
Comparing the lowest quartile with the highest quartile of total
testosterone or calculated free testosterone there were no sig-
nificant associations with RA risk in univariate analysis or after
adjusting for confounders (Table 2). For example, the top quar-
tile of calculated free testosterone level was associated with a
relative risk of 1.7 (95% confidence interval = 0.8 to 3.5). Sim-
ilarly for DHEAS, there was no evidence of increased RA risk
with low DHEAS in either univariate or multivariable analysis.
Stratified analyses among premenopausal women and post-
menopausal women and among seropositive or seronegative
RA had similar results (data not shown).
Androgen receptor polymorphisms and hormone levels 
in the NHS
There were modest associations between several AR SNPs
and plasma hormone levels among control samples (Table 3).
The variant genotypes for rs962458, rs6152, rs1204038 and
rs1337080 were associated with higher plasma calculated
free testosterone levels (P = 0.03, P = 0.03, P = 0.05 and P
= 0.03, respectively) and rs6152 was associated with total
testosterone (P = 0.04). We found no significant association
between the length of the AR CAG repeat and hormone levels
among 89 control samples (data not shown).
Androgen receptor polymorphisms in the NHS and the 
WHS
Using a dominant model there was no association with RA for
any of the six htSNPs in the NHS, in the WHS, and in the
pooled sample with 522 cases and 662 controls in adjusted
analyses (see Table S1 in Additional data file 1). In pooledArthritis Research & Therapy    Vol 11 No 3    Karlson et al.
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analyses, with stratification into rheumatoid factor-positive and
rheumatoid factor-negative RA, the odds ratios were modestly
elevated for rheumatoid factor-positive RA but remained non-
significant (see Table S2 in Additional data file 1). Haplotype
analysis had similar null results (Table 4). There was no evi-
dence for any interaction between the six htSNPs in the andro-
gen receptor and cigarette smoking classified as never/ever
smoked in the combined analysis, or classified as never/≤ 10
pack-years of smoking versus >10 pack-years of smoking in
the NHS analysis (data not shown). We found no significant
association between the length of the AR CAG repeat and RA
risk (data not shown).
ESR2, PGR, and CYP19 polymorphisms in the NHS and 
the WHS
For ESR2, PGR and CYP19, none of the individual htSNPs
were significantly associated with RA. A single haplotype in
ESR2 and a single haplotype in PGR were associated with
RA; however, the global tests for haplotype association were
not significant for ESR2 (P = 0.06) and for PGR (P = 0.21)
Table 1
Characteristics of rheumatoid arthritis cases and matched controls in the NHS and WHS
NHS
(449 cases/449 controls)
WHS
(72 cases/202 controls)
RA cases Controls RA cases Controls
Matching factors
Age at blood draw 55 ± 8 55 ± 8 55 ± 8 55 ± 8
Postmenopausala 179 (67%) 179 (67%) 39 (54%) 109 (54%)
Current postmenopausal hormone use 92 (34%) 93 (35%) 37 (51%) 104 (51%)
Other characteristics
Ever cigarette smokers 272 (61%) 252 (56%) 46 (64%) 106 (52%)
Pack-years among smokers 23 ± 16 23 ± 20 - -
Parous 411 (92%) 420 (94%) 62 (86%) 180 (89%)
Breastfed babies ≥ 12 months totalb 67 (15%) 81 (18%) - -
Age at menarche <12 years 107 (24%) 96 (22%) 18 (25%) 47 (23%)
Irregular menstrual cycles 66 (15%) 61 (14%) - -
Body mass index (kg/m2) 26 ± 5 26 ± 5 26 ± 6 26 ± 5
Rheumatoid arthritis characteristics
Age at diagnosis 55 ± 10 61 ± 8
Rheumatoid factor positive 260 (58%) 42 (58%)
Cyclic citrullinated antibody positivec 73 (55%) -
Rheumatoid nodules 59 (13%) 9 (13%)
Radiographic changes 137 (31%) 15 (21%)
Hormone levelsd
Free testosterone (pg/ml) 0.06 (0.03) 0.06 (0.03)
Free testosterone (pg/ml) 0.06 (0.05 to 0.08) 0.06 (0.04 to 0.08)
Total testosterone (pg/ml) 22.0 ± 10.0 21.7 ± 11.1
Total testosterone (pg/ml) 22.0 (16.0 to 31.0) 21.0 (16.0 to 29.0)
DHEAS (pg/ml) 91.1 ± 68.9 87.5 ± 59.0
DHEAS (pg/ml) 72.1 (38.5 to 113.9) 69.0 (46.0 to 116.4)
Data presented as mean ± standard deviation, n (%) or median (25th to 75th percentile). aPercentage is calculated among postmenopausal 
women or parous women, with unknown/missing group excluded. For the rest of the variables, percentage was calculated with missing category 
included. bCalculated among parous women in the Nurses' Health Study (NHS), data not available in the Women's Health Study (WHS). cCyclic 
citrullinated peptide antibodies tested in 132 preclinical rheumatoid arthritis (RA) samples. dMeasured in NHS samples for free and total 
testosterone and dehydroepiandrosterone sulfate (DHEAS) (n = 132 rheumatoid arthritis cases, n = 396 controls).Available online http://arthritis-research.com/content/11/3/R97
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(Table 4). There was no association for haplotypes in CYP19,
blocks 2, 3, or 4 (data not shown). There were four haplotypes
in CYP19, block 1 that were modestly associated with RA in
adjusted analyses (Table 4), with a significant global test for
haplotype association (P = 0.02). None of these findings were
significant after adjustment for multiple comparisons.
Discussion
We found no evidence that women with pre-RA have lower
plasma androgen levels than matched control individuals in
this nested case–control study that included 132 incident RA
cases with plasma blood samples collected prior to disease
onset and 396 controls. This finding is consistent with a case–
control study nested in a Finnish cohort of 19,072 subjects,
which demonstrated no differences in concentration of total
testosterone and DHEAS measured in stored serum speci-
mens collected up to 16 years prior to diagnosis between 116
pre-RA cases (32 men, 84 women) and controls [18]. Serum
SHBG was not measured in that study, and therefore the bio-
logically active form – free testosterone – could not be deter-
mined. In contrast, a smaller study demonstrated low DHEAS
among 11 premenopausal pre-RA women compared with
control individuals, with levels measured 7 to 18 years prior to
RA onset. In stratified analyses, however, we could not confirm
an association between DHEAS and RA in premenopausal
women. The observed androgen deficiency reported in the lit-
erature in existing RA [6-10] is most probably a consequence
of the disease, and not causal.
In a small sample of 89 controls with both genotype and
plasma hormone results, we demonstrated that four of the AR
SNPs were associated with higher free testosterone levels –
suggesting that these polymorphisms may have functional
effects, although the sample size is small. We found no evi-
dence, however, of polymorphisms in the AR gene being asso-
ciated with RA risk in unadjusted analyses or after adjustment
for potential confounders. Similarly, none of the individual pol-
ymorphisms in ESR2, PGR, and CYP19 or in the AR CAG
repeat was associated with RA risk. There was some modest
evidence for haplotype associations in ESR2,  PGR  and
CYP19, block 1; however, none of these results were signifi-
cant after adjustment for multiple comparisons.
Studies regarding repeat polymorphisms in AR suggest asso-
ciations between CAG repeat length and clinical features of
RA but no association with RA susceptibility [58-60]. Associ-
ations regarding ESR2 repeat polymorphisms and clinical fea-
tures of RA have been reported [61,62]. An association
between CYP19 and RA was reported in a linkage study [63].
No case–control association studies for SNPs or haplotypes,
however, have been reported for AR,  ESR2,  PGR, and
CYP19. None of the published genome-wide association
Table 2
Rheumatoid arthritis associated with quartiles of plasma androgens in the Nurses' Health Studies
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trenda P continuousb
Free testosterone
Median (controls) 0.028 0.046 0.061 0.085
Cases/controls 25/98 36/98 37/98 33/98
Unadjustedc 1.0 1.6 (0.8 to 2.9) 1.7 (0.9 to 3.2) 1.5 (0.8 to 3.0) 0.36 0.51
Adjustedd 1.0 1.5 (0.8 to 2.8) 1.6 (0.8 to 3.3) 1.7 (0.8 to 3.5) 0.24 0.44
Total testosterone
Median (controls) 11.0 18.0 23.0 34.0
Cases/controls 32/104 33/103 31/96 36/92
Unadjustedc 1.0 1.1 (0.6 to 1.9) 1.1 (0.6 to 2.1) 1.4 (0.7 to 2.5) 0.32 0.75
Adjustedd 1.0 1.1 (0.6 to 2.0) 1.2 (0.6 to 2.4) 1.5 (0.8 to 2.9) 0.20 0.52
Dehydroepiandrosterone sulfate
Median (controls) 30.58 56.16 93.10 158.20
Cases/controls 40/98 20/98 37/98 34/98
Unadjustedc 1.0 0.5 (0.3 to 0.9) 0.9 (0.5 to 1.6) 0.8 (0.5 to 1.5) 0.85 0.51
Adjustedd 1.0 0.5 (0.3 to 1.0) 0.9 (0.5 to 1.5) 0.7 (0.4 to 1.4) 0.66 0.71
Data presented as relative risk (95% confidence interval), n = 132 preclinical rheumatoid arthritis cases/396 controls. aCalculated using median 
hormone level in each quartile and the Wald chi-square test. bCalculated using continuous hormone levels and the Wald chi-square test. 
cConditional logistic regression conditioned on strata defined by matched factors. dConditional logistic regression conditioned on matching 
factors, adjusted for body mass index (continuous), cigarette smoking (never, past, current smoker <15 cigarettes per day, current smoker ≥ 15 
cigarettes per day), age at menarche, menstrual regularity, parity, breastfeeding.Arthritis Research & Therapy    Vol 11 No 3    Karlson et al.
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studies have reported significant findings for these genes
either [64,65].
The prospective design of these cohorts allowed us to study
plasma androgen levels up to 14 years prior to RA onset and
to adjust for a number of potential confounders such as ciga-
rette smoking and reproductive factors. There were several
limitations to the study design, however, including the small
number of incident RA cases after the blood collection, which
limited the power to detect hormone associations, and the lack
of repeated blood samples at multiple timepoints prior to RA.
Data from the NHS, however, indicate that a single sample
reflects long-term hormone levels reasonably well. For
instance, postmenopausal hormone levels measured three
times over a 3-year period in 79 women from the NHS reliably
categorized average levels with intraclass correlations of 0.88
for testosterone, 0.88 for DHEAS, and 0.92 for SHBG [66].
We studied plasma androgens rather than local androgen lev-
els such as synovial fluid levels that may be more indicative of
an altered estrogen–androgen balance in the pathophysiology
of RA [14]. With 132 cases and 396 controls we have 80%
power to detect an odds ratio of 0.38 for the top quartile as
compared with the lowest quartile. For the genetic analyses,
we limited the analysis to women with self-reported Caucasian
ancestry to minimize population stratification, and other stud-
ies have reported little stratification in this cohort [67]. With
Table 3
Association of AR haplotype-tag polymorphisms and plasma hormone levels in the Nurses' Health Studies
AR SNP Dehydroepiandrosterone sulfatea Total testosteroneb Free testosteronec
rs962458
CC 96.6 ± 12.6 23.2 ± 1.4 0.062 ± 0.003
CT/TT 98.5 ± 19.2 30.2 ± 3.4 0.081 ± 0.008
P value 0.91 0.06 0.03
rs6152
AA 84.7 ± 14.0 22.5 ± 1.5 0.060 ± 0.004
AG/GG 109.8 ± 14.4 28.8 ± 2.6 0.076 ± 0.006
P value 0.07 0.04 0.03
rs1204038
TT 86.7 ± 14.3 22.1 ± 1.5 0.059 ± 0.004
TC/CC 104.9 ± 13.8 27.4 ± 2.2 0.073 ± 0.006
P value 0.17 0.06 0.05
rs2361634
GG 97.1 ± 12.5 24.2 ± 1.4 0.064 ± 0.003
GA/AA 92.1 ± 19.1 24.3 ± 3.4 0.067 ± 0.008
P value 0.76 0.96 0.71
rs1337080
GG 96.4 ± 12.5 23.2 ± 1.4 0.061 ± 0.003
GA/AA 98.6 ± 19.1 30.2 ± 3.4 0.080 ± 0.008
P value 0.89 0.06 0.03
rs1337082
GG 87.1 ± 14.4 22.7 ± 1.8 0.060 ± 0.004
GA/AA 101.8 ± 13.2 25.4 ± 1.9 0.068 ± 0.005
P value 0.22 0.32 0.20
Androgen receptor gene (AR) association in 89 controls from the Nurses' Health Studies. Data presented as mean ± standard deviation. aAnalysis 
of covariance adjusted for age (continuous), body mass index (continuous), menopausal status and postmenopausal hormone use, cigarette 
smoking (never, past, current smoker <15 cigarettes per day, current smoker ≥ 15 cigarettes per day) and time of day of blood draw. bAnalysis of 
covariance adjusted for age (continuous), body mass index (continuous), menopausal status and postmenopausal hormone use, and cigarette 
smoking (never, past, current smoker <15 cigarettes per day, current smoker ≥ 15 cigarettes per day). cAnalysis of covariance adjusted for age 
(continuous), body mass index (continuous), menopausal status and postmenopausal hormone use, and cigarette smoking (never, past, current 
smoker <15 cigarettes per day, current smoker ≥ 15 cigarettes per day).Available online http://arthritis-research.com/content/11/3/R97
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521 cases and 651 controls, we had 86% power to detect an
odds ratio of 1.5 for minor allele frequencies of 15%, but only
27% power to detect odds ratios of 1.2. The power to detect
modest odds ratios, such as those demonstrated in recent
genome-wide association studies in RA [68-70], was there-
fore quite limited.
Conclusions
Although the possibility of a biologic relationship between AR,
androgen levels, and RA risk is intriguing, our findings do not
suggest that AR is related to RA risk in women. We do not
show any significant associations for other hormone-related
genes, ESR2, PGR and CYP19 and RA risk after adjustment
for multiple comparisons. Steroid hormone levels measured at
a single timepoint from 0 to 14 years prior to RA onset were
not associated with RA risk in the present study. In conclusion,
among women in the NHS, NHS II and WHS, neither hormone
receptor genes nor plasma steroid hormone levels are associ-
ated with RA risk.
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1 haplotype-tagged SNPs: rs2446405-rs2445765-rs2470144-rs2445762-rs1004984-rs1902584; global haplotype association, P = 0.02.Arthritis Research & Therapy    Vol 11 No 3    Karlson et al.
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